Cristcot to Present Data on Novel Ulcerative Colitis Treatment at the American College of Gastroenterology 2025 Annual Meeting

Cristcot to Present Data on Novel Ulcerative Colitis Treatment at the American College of Gastroenterology 2025 Annual Meeting

CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas,October 25, 2025 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in...